Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 19;14:1180404. doi: 10.3389/fendo.2023.1180404

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Zhao, Wang, Ding, Ye, Cheng, Shao, Liu and Zhou

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Immunotherapy and chemotherapy in different risk groups. (A) Proportions of response to anti-PD-L1 immunotherapy in high- and low-risk groups. (B) Differences in risk scores between different response groups in the IMvigor210 cohort. (C) Proportions of response to immunotherapy in high- and low-risk groups based on TIDE results. (D) Differences in TIDE scores between high- and low-risk groups. (E–H) Differences in chemotherapy sensitivity of Doxorubicin, Gemcitabine, Lapatinib, and Sunitinib among different risk groups. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. *p<0.05.